Cytokine profiles in stem cell transplantation: Possible use as a predictor of graft-versus-host disease

Hematology

Volumn 10, Issue 2, 2005, Pages 107-114

  Lunn, R A ^a   Sumar, N ^a   Bansal, A S ^a   Treleaven, J ^b  

^a ST HELIER HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Graft versus host disease; IL 2; sFas; Transforming growth factor; Tumour necrosis factor; Vascular endothelial growth factor

Indexed keywords

CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER; FAS ANTIGEN; IL2RA PROTEIN, HUMAN; INTERLEUKIN RECEPTOR; VASCULOTROPIN A;

ALLOGRAFT; ARTICLE; AUTOGRAFT; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD; FANCONI ANEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; PREDICTION AND FORECASTING;

ANTIGENS, CD95; BIOLOGICAL MARKERS; CYTOKINES; FANCONI ANEMIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24644436976     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330400001975     Document Type: Article

References (36)

1. Christiansen FT, Witt CS. Allogeneic bone marrow transplantation. In: Bradley J, McCluskey J, editors. Clinical immunology. Oxford: Oxford University Press; 1997. p 442-459.
2. Beatty PG, Hansen JA. Bone marrow transplantation for the treatment of haematologic disease: status in 1992. Bone Marrow Transplant 1993;7:1123-1129.
3. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Transplantation 1999;67:509-513.
4. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, Harada M, Niho Y. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17:185-190.
5. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995;16:747-753.
6. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high risk patients. Bone Marrow Transplant 1994;14(Suppl. 4):56-60.
7. Barrett AJ, van Rhee F. Graft-versus-leukaemia. Baillieres Clin Haematol 1997;10:337-355.
8. Holler E, Kolb HJ, Moller Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mitterm C. Increased serum levels of tumour necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011-1016.
9. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998;66:863-871.
10. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-838.
11. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 88:193-214.
12. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983;62:941-964.
13. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG. Bone marrow transplantation for patients with chronic myeloid leukaemia. N Engl J Med 1986;314:202-207.
14. For the European Group for blood and marrow transplantation Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplantation activity in Europe since 1995. Bone Marrow Transplant 1997;19:407-419.
15. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumara K. Graft-versus- leukaemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999;93:2738-2747.
16. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K. Differential effects of anti-Fas ligand and anti-tumor necrosis factor a antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055.
17. Liem LC, van Lopik T, van Nieuwenhuijze AEM, van Houwelingen HC, Aarden L, Goulmy E. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 1998;91:1464-1468.
18. Kanda Y, Tanaka Y, Shirakawa K, Yatomi T, Nakamura N, Kami M, Saito T, Izutsu K, Asai T, Yuji K, Ogawa S, Honda H, Mitani K, Chiba S, Yazaki Y, Hirai H. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 1998; 22:751-754.
19. Rozendaal L, Pals ST, Schilham M, Melief CJ, Gleichmann E. Allosuppression of B cells in vitro by graft-versus-host reaction derived T cells is caused by cytotoxic T lymphocytes. Eur J Immunol 1989;19:1669-1675.
20. + T cells. J Immunol 1995; 155:2396-2406.
21. Gleichmann E, Pals ST, Rolink AG, Radaszliewicz T, Gleichman H. Graft-versus-host reactions: clues to the etiopathology of spectrum of immunological disease. Immunol Today 1984;5:324-329.
22. De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C, Abramowicz D, Scheerlinck JP, De Baetselier P, Urbain J. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993;150:361-366.
23. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-673, In: Epstein FH (editor) Mechanisms of Disease: Review Article.
24. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172-3177.
25. Siegert W, Josimovic-Alasevic O, Schwerdtfeger R, Baurmann H, Schmidt CA, Musch R, Schmid HJ, Hartmann R, Henze G, Huhn D. Soluble interleukin 2 receptors in patients after bone marrow transplantation. Bone Marrow Transplant 1990; 6:97-101.
26. Josimovic-Alasevic O, Feldmeier H, Zwingenberger K, Harms G, Hahn H, Shrisuphanunt M, Diamantstein T. Interleukin-2 receptor in patients with localized and systemic parasitic disease. Clin Exp Immunol 1988;72:249-254.
27. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-1456.
28. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995;14:1129-1135.
29. Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nat. Rev. Immunol 2002;2:46-53.
30. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derunck R, Sporn MB, Fauci AS. Production of transforming growth factor β by human T-lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 1986;163:1037-1050.
31. Brabletz T, Pfeuffer I, Schorr E, Siebelt F, Wirth T, Serfling E. Transforming growth factor β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol 1993;13:1155-1162.
32. Maeda H, Shiraishi A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-78.
33. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-β1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation 1999; 67:59-65.
34. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
35. Webb NJA, Myers CR, Watson CJ, Bottomly MJ, Brenchley PEC. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998;10:254-257.
36. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269:6271-6274.